David Einhorn
Greenlight Capital
David Einhorn ImmunovantInc stake
total: 357
Greenlight Capital IMVT trades
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, David Einhorn holds 93,520 ImmunovantInc (IMVT) shares with a market value of roughly $3.60M accounting for 0.09% of the overall portfolio. To date, the estimated cost basis is nearly $24.84 for "buy" trades. Greenlight Capital first purchased IMVT in 2026 Q1, initially acquiring 93,520 shares.
When did David Einhorn buy ImmunovantInc (IMVT)?
David Einhorn first invested in ImmunovantInc (IMVT) in 2026 Q1 at the reported quarter-end price of $24.84 per share.
What's the cost basis of Greenlight Capital's IMVT stake?
The estimated cost basis for ImmunovantInc (IMVT) stake is around $24.84 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $24.84
David Einhorn's historical trades in ImmunovantInc
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.07%
|
93,520
|
$24.84
|
$2,323,036
|
new
|
+0.07%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.